Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 2/2008

01.04.2008 | Review

Tissue factor, angiogenesis and tumour progression

verfasst von: Joanne E Bluff, Nicola J Brown, Malcolm WR Reed, Carolyn A Staton

Erschienen in: Breast Cancer Research | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Tissue factor, the primary initiator of the coagulation cascade, maintains vascular integrity in response to injury. It is now recognised that, in addition to the role as a procoagulant activator, tissue factor participates in many tumour-related processes that contribute to malignant disease progression. The present review details the recent evidence supporting a role for tissue factor in tumour haemostasis, angiogenesis, metastasis and malignant cell survival. Furthermore, future research directions are discussed that may enhance our understanding of the role and regulation of this protein, which could ultimately lead to the innovative design and development of new anticancer therapies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Fisher KL, Gorman CM, Vehar GA, O'Brien DP, Lawn RM: Cloning and expression of human tissue factor cDNA. Thromb Res. 1987, 48: 89-99. 10.1016/0049-3848(87)90349-5.CrossRefPubMed
2.
Morrissey JH, Fakhrai H, Edgington TS: Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell. 1987, 50: 129-135. 10.1016/0092-8674(87)90669-6.CrossRefPubMed
3.
Scarpati EM, Wen D, Broze GJ, Miletich JP, Flandermeyer RR, Siegel NR, Sadler JE: Human tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry. 1987, 26: 5234-5238. 10.1021/bi00391a004.CrossRefPubMed
4.
Spicer EK, Horton R, Bloem L, Bach R, Williams KR, Guha A, Kraus J, Lin TC, Nemerson Y, Konigsberg WH: Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA. 1987, 84: 5148-5152. 10.1073/pnas.84.15.5148.CrossRefPubMedPubMedCentral
5.
Mackman N: Alternatively spliced tissue factor – one cut too many?. Thromb Haemost. 2007, 97: 5-8.CrossRefPubMed
6.
Camerer E, Kolsto AB, Prydz H: Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 1996, 81: 1-41. 10.1016/0049-3848(95)00209-X.CrossRefPubMed
7.
Morrissey JH, Neuenschwander PF, Huang Q, McCallum CD, Su B, Johnson AE: Factor VIIa–tissue factor: functional importance of protein–membrane interactions. Thromb Haemost. 1997, 78: 112-116.PubMed
8.
Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ: Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res. 2006, 66: 7067-7074. 10.1158/0008-5472.CAN-06-0346.CrossRefPubMedPubMedCentral
9.
Moll T, Czyz M, Holzmuller H, Hofer-Warbinek R, Wagner E, Winkler H, Bach FH, Hofer E: Regulation of the tissue factor promoter in endothelial cells. Binding of NF kappa B-, AP-1-, and Sp1-like transcription factors. J Biol Chem. 1995, 270: 3849-3857. 10.1074/jbc.270.29.17064.CrossRefPubMed
10.
Zhang JJ, Kelm RJ, Biswas P, Kashgarian M, Madri JA: PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells. J Cell Physiol. 2007, 210: 527-537. 10.1002/jcp.20908.CrossRefPubMed
11.
Nadir Y, Brenner B, Zetser A, Ilan N, Shafat I, Zcharia E, Goldshmidt O, Vlodavsky I: Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost. 2006, 4: 2443-2451. 10.1111/j.1538-7836.2006.02212.x.CrossRefPubMed
12.
Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR: Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA. 1999, 96: 8663-8668. 10.1073/pnas.96.15.8663.CrossRefPubMedPubMedCentral
13.
Bluff JE, Brown NJ, Reed MWR, Staton CA: Assessment of angiogenesis, vascular endothelial growth factor and tissue factor in human breast Cancer [abstract]. Microcirculation. 2007, 14: P638-
14.
Ueno T, Toi M, Koike M, Nakamura S, Tominaga T: Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000, 83: 164-170. 10.1054/bjoc.2000.1272.CrossRefPubMedPubMedCentral
15.
Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR: Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 1998, 152: 399-411.PubMedPubMedCentral
16.
Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996, 2: 209-215. 10.1038/nm0296-209.CrossRefPubMed
17.
Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ, Reed MW: The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut. 2007, 56: 1426-1432. 10.1136/gut.2007.125286.CrossRefPubMedPubMedCentral
18.
Abid Hussein MN, Boing AN, Biro E, Hoek FJ, Vogel GM, Meuleman DG, Sturk A, Nieuwland R: Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. Thromb Res. 2007.
19.
Censarek P, Bobbe A, Grandoch M, Schror K, Weber AA: Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost. 2007, 97: 11-14.PubMed
20.
Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U: Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res. 2005, 96: 1233-1239. 10.1161/01.RES.0000171805.24799.fa.CrossRefPubMed
21.
Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA, Weltermann A: Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007, 97: 119-123.PubMed
22.
Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S: Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2007, 5: 520-527. 10.1111/j.1538-7836.2007.02369.x.CrossRefPubMed
23.
Chen VM, Hogg PJ: Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost. 2006, 4: 2533-2541. 10.1111/j.1538-7836.2006.02236.x.CrossRefPubMed
24.
Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W: Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA. 2006, 103: 13932-13937. 10.1073/pnas.0606411103.CrossRefPubMedPubMedCentral
25.
Versteeg HH, Ruf W: Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem. 2007, 282: 25416-25424. 10.1074/jbc.M702410200.CrossRefPubMed
26.
Pendurthi UR, Ghosh S, Mandal SK, Rao LV: Tissue factor activation: is disulfide bond switching a regulatory mechanism?. Blood. 2007, 110: 3900-3908. 10.1182/blood-2007-07-101469.CrossRefPubMedPubMedCentral
27.
Rak J, Milsom C, May L, Klement P, Yu J: Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost. 2006, 32: 54-70. 10.1055/s-2006-933341.CrossRefPubMed
28.
Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W: Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008, 111: 190-199. 10.1182/blood-2007-07-101048.CrossRefPubMedPubMedCentral
29.
Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W: Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007, 27: 1456-1462. 10.1161/ATVBAHA.107.142539.CrossRefPubMed
30.
Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W: Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004, 10: 502-509. 10.1038/nm1037.CrossRefPubMed
31.
Goldhaber SZ: Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation. 2005, 111: 539-541. 10.1161/01.CIR.0000156099.83394.A7.CrossRefPubMed
32.
Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004, 126: 715-721. 10.1111/j.1365-2141.2004.05078.x.CrossRefPubMed
33.
Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM: Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol. 2003, 21: 2192-2198. 10.1200/JCO.2003.08.046.CrossRefPubMed
34.
Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D: Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!. J Clin Oncol. 2002, 20: 1446-1448.PubMed
35.
Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS: In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 2005, 65: 5365-5373. 10.1158/0008-5472.CAN-04-3156.CrossRefPubMed
36.
Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G: Procoagulant factors in patients with cancer. Hematology. 2007.
37.
Uno K, Homma S, Satoh T, Nakanishi K, Abe D, Matsumoto K, Oki A, Tsunoda H, Yamaguchi I, Nagasawa T, Yoshikawa H, Aonuma K: Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007, 96: 290-295. 10.1038/sj.bjc.6603552.CrossRefPubMedPubMedCentral
38.
Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB: Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007, 13: 2870-2875. 10.1158/1078-0432.CCR-06-2351.CrossRefPubMed
39.
Hu T, Bach RR, Horton R, Konigsberg WH, Todd MB: Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol Res. 1994, 6: 321-327.PubMed
40.
Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ: PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005, 65: 1406-1413. 10.1158/0008-5472.CAN-04-3376.CrossRefPubMed
41.
Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005, 105: 1734-1741. 10.1182/blood-2004-05-2042.CrossRefPubMed
42.
Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y: Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003, 9: 458-462. 10.1038/nm841.CrossRefPubMed
43.
Bajaj MS, Ghosh M, Bajaj SP: Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications. J Thromb Haemost. 2007, 5: 1493-1499. 10.1111/j.1538-7836.2007.02604.x.CrossRefPubMed
44.
Chand HS, Ness SA, Kisiel W: Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer. 2006, 118: 1713-1720. 10.1002/ijc.21550.CrossRefPubMed
45.
Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82: 4-6. 10.1093/jnci/82.1.4.CrossRefPubMed
46.
Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR: A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001, 293: 1666-1670. 10.1126/science.1061259.CrossRefPubMed
47.
Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994, 94: 1320-1327. 10.1172/JCI117451.CrossRefPubMedPubMedCentral
48.
Zhang J, Ding J, Zhang X, Shao X, Hao Z: Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue factor (TF) in SGC-7901 gastric cancer cells. Cancer Biol Ther. 2005, 4: 769-772.CrossRefPubMed
49.
Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Müller M, Risau W, Edgington T, Collen D: Role of tissue factor in embryonic blood vessel development. Nature. 1996, 383: 73-75. 10.1038/383073a0.CrossRefPubMed
50.
Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS: Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003, 63: 2997-3000.PubMed
51.
Rao LV, Pendurthi UR: Tissue factor–factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005, 25: 47-56.PubMed
52.
Ahamed J, Ruf W: Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem. 2004, 279: 23038-23044. 10.1074/jbc.M401376200.CrossRefPubMed
53.
Dorfleutner A, Ruf W: Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation. Blood. 2003, 102: 3998-4005. 10.1182/blood-2003-04-1149.CrossRefPubMed
54.
Versteeg HH, Hoedemaeker I, Diks SH, Stam JC, Spaargaren M, van Bergen En Henegouwen PM, van Deventer SJ, Peppelenbosch MP: Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem. 2000, 275: 28750-28756. 10.1074/jbc.M907635199.CrossRefPubMed
55.
Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK, Jauch KW, Bruns CJ: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005, 105: 4463-4469. 10.1182/blood-2004-09-3540.CrossRefPubMed
56.
Albrektsen T, Sorensen BB, Hjorto GM, Fleckner J, Rao LV, Petersen LC: Transcriptional program induced by factor VIIa–tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007, 5: 1588-1597. 10.1111/j.1538-7836.2007.02603.x.CrossRefPubMedPubMedCentral
57.
Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 1998, 91: 2698-26703.PubMed
58.
Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoine NR: Enhanced expression of urokinase receptor induced through the tissue factor–factor VIIa pathway in human pancreatic cancer. Cancer Res. 1998, 58: 4461-4467.PubMed
59.
Camerer E, Rottingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG, Prydz H: Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem. 1999, 274: 32225-32233. 10.1074/jbc.274.45.32225.CrossRefPubMed
60.
Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV: Tissue factor–factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004, 103: 3029-3037. 10.1182/blood-2003-10-3417.CrossRefPubMedPubMedCentral
61.
Ge L, Ly Y, Hollenberg M, DeFea K: A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. J Biol Chem. 2003, 278: 34418-34426. 10.1074/jbc.M300573200.CrossRefPubMed
62.
Wiiger MT, Prydz H: The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells. Thromb Haemost. 2004, 92: 13-22.PubMed
63.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL: Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007, 110: 133-141. 10.1182/blood-2007-01-065995.CrossRefPubMedPubMedCentral
64.
Booden MA, Eckert LB, Der CJ, Trejo J: Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol. 2004, 24: 1990-1999. 10.1128/MCB.24.5.1990-1999.2004.CrossRefPubMedPubMedCentral
65.
Bluff JE, Mangera A, Brown NJ, Reed MWR, Staton CA: Tissue factor and vascular endothelial growth factor in breast cancer [abstract]. Angiogenesis. 2006, 9: P31-
66.
Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W: A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol. 1998, 140: 1241-1253. 10.1083/jcb.140.5.1241.CrossRefPubMedPubMedCentral
67.
Siegbahn A, Johnell M, Rorsman C, Ezban M, Heldin CH, Ronnstrand L: Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood. 2000, 96: 3452-3458.PubMed
68.
Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME: Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost. 2004, 2: 93-101. 10.1111/j.1538-7836.2004.00545.x.CrossRefPubMed
69.
Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J: Pro-tease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006, 66: 307-314. 10.1158/0008-5472.CAN-05-1735.CrossRefPubMed
70.
Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W: Crosstalk of integrin α3β1 and tissue factor in cell migration. Mol Biol Cell. 2004, 15: 4416-4425. 10.1091/mbc.E03-09-0640.CrossRefPubMedPubMedCentral
71.
Siegbahn A, Johnell M, Sorensen BB, Petersen LC, Heldin CH: Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost. 2005, 93: 27-34.PubMed
72.
Ott I, Weigand B, Michl R, Seitz I, Sabbari-Erfani N, Neumann FJ, Schomig A: Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation. 2005, 111: 349-355. 10.1161/01.CIR.0000153333.52294.42.CrossRefPubMed
73.
Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM: CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007, 120: 1261-1267. 10.1002/ijc.22426.CrossRefPubMed
74.
Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H: Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res. 2006, 12: 4055-4061. 10.1158/1078-0432.CCR-05-2482.CrossRefPubMed
75.
Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A: Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA. 1995, 92: 8205-8209. 10.1073/pnas.92.18.8205.CrossRefPubMedPubMedCentral
76.
Mueller BM, Reisfeld RA, Edgington TS, Ruf W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA. 1992, 89: 11832-11836. 10.1073/pnas.89.24.11832.CrossRefPubMedPubMedCentral
77.
Mueller BM, Ruf W: Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 1998, 101: 1372-1378. 10.1172/JCI930.CrossRefPubMedPubMedCentral
78.
Bromberg ME, Bailly MA, Konigsberg WH: Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb Haemost. 2001, 86: 1210-1214.PubMed
79.
Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H, Ushijima T: Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer. 2007, 121: 301-307. 10.1002/ijc.22637.CrossRefPubMed
80.
Dimmeler S, Zeiher AM: Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res. 2000, 87: 434-439.CrossRefPubMed
81.
Jiang X, Guo YL, Bromberg ME: Formation of tissue factor–factor VIIa–factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost. 2006, 96: 196-201.PubMed
82.
Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC: Antiapoptotic effect of coagulation factor VIIa. Blood. 2003, 102: 1708-1715. 10.1182/blood-2003-01-0157.CrossRefPubMed
83.
Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP: Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene. 2004, 23: 410-417. 10.1038/sj.onc.1207066.CrossRefPubMed
84.
Versteeg HH, Spek CA, Slofstra SH, Diks SH, Richel DJ, Peppelenbosch MP: FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production. Circ Res. 2004, 94: 1032-1040. 10.1161/01.RES.0000125625.18597.AD.CrossRefPubMed
85.
Li C, Colman LM, Collier ME, Dyer CE, Greenman J, Ettelaie C: Tumour-expressed tissue factor inhibits cellular cytotoxicity. Cancer Immunol Immunother. 2006, 55: 1301-1308. 10.1007/s00262-006-0130-1.CrossRefPubMed
86.
Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002, 87: 930-936.PubMed
87.
Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL: Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003, 63: 5046-5053.PubMed
88.
Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen A, Deisseroth A: Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther. 2007, 14: 346-353. 10.1038/sj.cgt.7701030.CrossRefPubMed
89.
Morrow DA, Murphy SA, McCabe CH, Mackman N, Wong HC, Antman EM: Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J. 2005, 26: 682-688. 10.1093/eurheartj/ehi094.CrossRefPubMed
Metadaten
Titel
Tissue factor, angiogenesis and tumour progression
verfasst von
Joanne E Bluff
Nicola J Brown
Malcolm WR Reed
Carolyn A Staton
Publikationsdatum
01.04.2008
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 2/2008
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1871

Weitere Artikel der Ausgabe 2/2008

Breast Cancer Research 2/2008 Zur Ausgabe

Research article

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

Research article

Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk

Viewpoint

Breast cancer metastasis: a microRNA story

Research article

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Research article

Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG)

Research article

Evaluation of biological pathways involved in chemotherapy response in breast cancer

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise